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ABSTRACT
The two G protein-coupled receptors (GPCRs) C-X-C chemo-
kine receptor type 4 (CXCR4) and atypical chemokine receptor
3 (ACKR3) are part of the class A chemokine GPCR family and
represent important drug targets for human immunodeficiency
virus (HIV) infection, cancer, and inflammation diseases. CXCR4
is one of only three chemokine receptors with a US Food and
Drug Administration approved therapeutic agent, the small-
molecule modulator AMD3100. In this review, knownmodulators
of the two receptors are discussed in detail. Initially, the structural
relationship between receptors and ligands is reviewed on the
basis of common structuralmotifs and available crystal structures.
To date, no atypical chemokine receptor has been crystallized,
which makes ligand design and predictions for these receptors
more difficult. Next, the selectivity, receptor activation, and the
resulting ligand-induced signaling output of chemokines and
other peptide ligands are reviewed. Binding of pepducins, a class
of lipid-peptides whose basis is the internal loop of a GPCR, to
CXCR4 is also discussed. Finally, small-molecule modulators of
CXCR4 and ACKR3 are reviewed. These modulators have led to
the development of radio- and fluorescently labeled tool com-
pounds, enabling the visualization of ligand binding and receptor
characterization both in vitro and in vivo.
SIGNIFICANCE STATEMENT
To investigate the pharmacological modulation of CXCR4 and
ACKR3, significant effort has been focused on the discovery and
development of a range of ligands, including small-molecule
modulators, pepducins, and synthetic peptides. Imaging tools,
such as fluorescent probes, also play a pivotal role in the field of
drug discovery. This review aims to provide an overview of the
aforementioned modulators that facilitate the study of CXCR4
and ACKR3 receptors.
Introduction
Chemokine receptors are a family of 24 seven-transmembrane
(7TM) domain G protein-coupled receptors (GPCRs) that
respond to chemokines, a class of 52 chemotactic cytokines
(Bachelerie et al., 2013). The chemokine-chemokine receptor
system is involved in the regulation of immune response,
inflammation, and cancer (Scholten et al., 2012). In this
review we focus on two related chemokine receptors, C-X-C
chemokine receptor type 4 (CXCR4) and atypical chemokine
receptor 3 (ACKR3), both binding the chemokine C-X-C
chemokine ligand 12 (CXCL12). CXCR4 function is critical
for the localization of hematopoietic stem cells, for binding of
HIV-1 to T-cell-tropic strains, and cancer cell development
(Feng et al., 1996; Horuk, 1999; Chatterjee et al., 2014;
Pozzobon et al., 2016; Teixidó et al., 2018; Neves et al., 2019).
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ACKR3, also known as C-X-C chemokine receptor type
7 (CXCR7), is not a classic GPCR and signals primarily
through b-arrestin recruitment (Rajagopal et al., 2010) and
therefore belongs to the class of atypical chemokine receptors
(ACKRs). The properties of the ACKR3-CXCL12 and
ACKR3-C-X-C chemokine ligand 11 (CXCL11) axes make
them promising therapeutic targets (Nibbs and Graham,
2013; Sánchez-Martín et al., 2013; Benhadjeba et al., 2018;
Quinn et al., 2018; Wang et al., 2018; Koenen et al., 2019).
Modulation of CXCL12-scavenging activity of ACKR3 regu-
lates CXCR4 function (Abe et al., 2014). Both receptors form
heterodimers (Levoye et al., 2009; Fumagalli et al., 2019) and
play an important role in CXCL12 biology (Hattermann and
Mentlein, 2013; Krikun, 2018; Murphy and Heusinkveld,
2018). The CXCR4/ACKR3/CXCL12 system remains a con-
temporary target for therapeutic application, and the de-
velopment of novel, potent, and selective modulators is of
great interest to both academia and the pharmaceutical
industry.
Pharmacological modulation of CXCR4 and ACKR3 has
been of great interest, and considerable effort has been
devoted to the discovery and development of a range of
ligands, including small-molecule modulators, pepducins,
synthetic peptides, and imaging tools such as fluorescent
probes. This review aims to give a concise overview of such
modulators.
Structural Determinants of Chemokine Receptor
Ligand Binding
Chemokine receptor structures consist of seven a-helical
TM (7TM) domains, linked through three extracellular (ECL)
and three intracellular (ICL) loops,withanN- andaC-terminus
(Fig. 1A). Features that define chemokine receptor structures
Fig. 1. (A) Overview of the CXCR4 crystal structure (gray cartoon) bound to the small-molecule antagonist IT1t (green sticks, PDB ID: 3ODU) (Wu et al.,
2010) and the synthetic peptide antagonist CVX15 (cyan cartoon and sticks, PDB ID: 3OE0) (Wu et al., 2010). (B) Binding details of IT1t to CXCR4. Side
chains of relevant interacting residues are shown in gray sticks, and the CVX15 surface is shown transparent for reference. (C) IT1t-bound CXCR4 two-
dimensional interaction map. Ionic interactions are represented as red dashed lines; hydrophobic contacts are represented as green lines. (D) Binding
details of CVX15 to CXCR4. Side chains of relevant interacting residues are shown in gray sticks and IT1t surface is shown transparent for reference. (E)
CVX15-bound CXCR4 two-dimensional interaction scheme. Ionic interactions are represented as red dashed lines; hydrogen bonds are represented as
blue dashed lines; hydrophobic contacts are represented as green lines. (F) CXCR4map of relevant residues (C-alpha shown as yellow spheres) for small-
molecule binding and/or function as proven by site-directedmutagenesis (SDM) experiments. IT1t is shown as green sticks as a reference. (G) CXCR4map
of relevant residues for signaling of CXCL12 (C-alpha shown as blue spheres), peptidomimetics (orange spheres), or both (magenta spheres), as proven by
SDM. Viral macrophage inflammatory protein-II (vMIP-II) is shown as transparent purple spheres as a reference. (H) CCX777 two-dimensional
predicted-interaction map. Hydrophobic contacts predicted through mutant experiments are represented as green lines.
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include a particular helix positioning where the top of TM2 is
tilted owing to the presence of the T2.56xP2.58 motif, a feature
that is shared with other protein and peptide receptors (e.g.,
opioid receptors); a highly conserved disulfide bridge between
the N-terminus and ECL3; the open, solvent-accessible 7TM
domain; and a diversity of druggable pockets, in line with
the chemical diversity among chemokine receptor ligands
(Arimont et al., 2017).
The endogenous ligands of chemokine receptors, chemo-
kines (Fig. 2, A and B), are thought to bind in a two-step
process: 1) The globular core of the chemokine binds to the
N-terminus and extracellular loops of the receptor, allowing
2) the N-terminus of the chemokine to bind in the 7TMdomain
(Kufareva et al., 2014). The orthosteric pocket of chemokine
receptors can be divided into a minor or small pocket, formed
by residues in TM1–TM3, and TM7, and a major pocket,
composed of residues in TM3–TM7. This binding site is wider
and more solvent-accessible than that in aminergic GPCRs,
and it contains a high number of negatively charged residue
side chains that are often involved in ligand binding (Arimont
et al., 2017). The negatively charged pocket of chemokine
receptors is complementary to the positively charged nature of
most of their ligands. Finally, X-ray and site-directed muta-
genesis studies have proven the existence of an intracellular
binding site that can be targeted by small molecules (de Kruijf
et al., 2011; Scholten et al., 2014; Oswald et al., 2016; Zheng
et al., 2016) and potentially by nanobodies, as exemplified by
the stabilizing nanobody Nb7 (Burg et al., 2015).
CXCR4 crystal structures reveal how chemokine receptors
are regulated by different types of modulators, which bind in
different (sometimes overlapping) binding pockets. The small-
molecule isothiourea IT1t (Wu et al., 2010) binds exclusively
in the minor pocket (Fig. 1B), where it makes ionic interac-
tions with D972.63x63 and E2887.39x38 (Fig. 1C). The synthetic
peptide CVX15 (Wu et al., 2010) binds into the major pocket
(Fig. 1D) and makes interactions with D1714.60x61 and
D2626x58x58 (Fig. 1E). Site-directed mutagenesis studies prove
that binding of small-molecule ligands is not limited to the
minor pocket. Rather, ligands can bind either the minor or
major subpocket, or both (Fig. 1F). Binding of peptides and
peptidomimetics often overlaps with the chemokine binding
site (Fig. 1G) and comprises residues in the extracellular
surface of the receptor, as well as more buried residues within
the TM bundle, where it overlaps with small molecules.
Fig. 2. Structure and structure-activity relationship of chemokine derivatives and peptidomimetics targeting CXCR4 and ACKR3. (A) Sequence
alignment of chemokines CXCL11, CXCL12, and vMIP-II. The different domains and motifs are indicated on top. SAR is indicated in gray boxes.
(B) Conserved tertiary structure of chemokines with CXCL12 crystal structure as a basis (PDB ID: 3GV3) (Murphy et al., 2010). The main structural
motifs are conserved among different chemokines, including a free, flexible N-terminus (green) linked through a 310 loop to the globular core of the
chemokine (gray), consisting of three antiparallel b-strands and a C-terminus a-helix (Scholten et al., 2014). This tertiary structure is maintained
through one or more disulfide bridges (yellow), the number and spacing of which allow for classification of chemokines in the C-, CC-, CXC-, and CX3C-
subfamilies. (C) Sequence and SAR of CXCR4 representative peptidomimetic modulators T22, T134, and FC131. SAR is indicated in gray boxes.
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However, neither IT1t nor CVX15 fully overlap with the
binding pocket of CXCL12 or viral macrophage inflammatory
protein-II (vMIP-II) (Fig. 1, F and G). The partial overlap
between the sites of chemokines, peptides, and small mole-
cules explains the allosteric nature of a number of chemokine
receptor ligands (Wu et al., 2010).
No ACKR3 crystal structures are available to date, and
information on ACKR3 modulators is still scarce. The identi-
fication of the binding mode of ACKR3 modulators is there-
fore very challenging. Only one study on ACKR3 modulators
reported potential interactions with the small molecule
CCX777 (Gustavsson et al., 2017), but no key ionic inter-
actions were identified (Fig. 1H). The lack of structural
information and the challenging nature of chemokine recep-
tor binding sites reflect the low success rate of drug discov-
ery campaigns on noncrystallized receptors like ACKR3
(Oishi et al., 2015).
Chemokine and Peptide Binding to CXCR4 and
ACKR3
CXCR4 and ACKR3 both bind the natural chemokine
CXCL12 (Hesselgesser et al., 1998; Balabanian et al., 2005),
the viral chemokine vMIP-II (Kledal et al., 1997; Szpakowska
et al., 2016), and other endogenous proteins such asb-defensins
2 and 3 (Quiñones-Mateu et al., 2003; Feng et al., 2006). ACKR3
also binds CXCL11 (Burns et al., 2006) and adrenomedullin
(Klein et al., 2014), and CXCR4 is reported to bind ubiquitin
(Saini et al., 2010). For more than two decades, multiple
studies focused on obtaining new or improved ligands using
modifications of natural protein ligands as a basis to mimic
their function. These modifications include point mutations,
truncations, fragmentation, and the generation ofmimetics and
chimeras. An overview of chemokines, peptide, peptidomimet-
ics, and modifications thereof that bind CXCR4 and/or ACKR3
is contained in Supplemental Table 1.
A number of studies focusing on mutagenesis of the
endogenous agonists CXCL11 and CXCL12 allow the evalu-
ation of the structural requirements for their activity (Fig. 2A).
Importantly, the first two residues of CXCL12 are key for
CXCR4 activity, as their mutation transforms it into an
antagonist with lower affinity (Crump et al., 1997; Loetscher
et al., 1998). Moreover, peptidomimetics of the N-terminus of
the chemokines (Fig. 2B) are sufficient to promote CXCR4
and ACKR3 activity, which will allow the use of smaller
and bioavailable peptide ligands as potential candidates for
further drug discovery (Crump et al., 1997; Loetscher et al.,
1998; Zhou et al., 2002; Ehrlich et al., 2013; Xu et al., 2013;
Mo and Sun, 2015; Szpakowska et al., 2018).
Most CXCR4 peptide and peptide-like modulators are
derivatives of polyphemusin II, a peptide isolated from
immune cells of the horseshoe crab Limulus polyphemus
(Murakami et al., 1997). The first reported CXCR4 antago-
nist analog of polyphemusin II, the 18-amino acid peptide
T22 (Fig. 2C), inhibits the ability of HIV-1 to infect cells
(Murakami et al., 1997). Since then, multiple studies have
focused on the improvement of this peptide in terms of affinity;
potency; biostability; and absorption, distribution, metabo-
lism, excretion (ADME) properties, often through the incor-
poration of unnatural amino acids and always keeping a cyclic
structure. Structure activity relationship (SAR) studies of T22
indicate that the presence of the disulfide loops and the
amount of positive charges are key for anti-HIV activity
(Tamamura et al., 1998a). Reducing the length and amount
of disulfide bridges of T22 leads to peptides with higher
potency without a significant change in secondary structure,
such as in the peptide TW70 (Tamamura et al., 1998b).
To stabilize the b-turn conformation in TW70, the unnatural
amino acid D-Lys was introduced as a D-Lys-Pro motif into
TW70. T22 and TW70 are highly basic peptides (eight
positively charged residues), and as a consequence they show
high collateral cytotoxicity. Analogs with reduced positive
charges, such as T134, have higher selectivity indexes com-
pared with T22 and TW70, which has been attributed to
a decrease in cytotoxicity (Tamamura et al., 1998c) (Fig. 2C).
Modification of a tryptophan in the sequence of T134 by
a naphthyl-alanine results in a 5-fold higher anti-HIV activity
than the lead peptide, as in the peptide T140 (Tamamura
et al., 1998d). Amidation of the T140 C-terminus (TZ14004)
increases the stability in serum but adds a positive charge,
increasing cytotoxicity (Tamamura et al., 2001). Modification
of positively charged residues by citrulline residues (x1 in
TN14003, x2 in TC14012), in addition to the amidation, yields
highly potent, less cytotoxic, and stable peptides (Tamamura
et al., 2001). TC14012 has also proven to be an agonist of
ACKR3 (Gravel et al., 2010). To improve biostability and keep
selectivity and cytotoxicity in balance, a series of substitutions
of Arg and/or Lys by Glu were designed, with an additional
N-alkyl-amidation at the N-terminus. This yielded the
(Ac-) TE14011 series (Tamamura et al., 2003a,b). Other
N-terminal substitutions of TE14011 were also designed to
prevent biodegradation, including guanylation (TF14002),
Na-tetramethylguanylation (TF14003), and Na-benzoylation
(TF14013 or 4F-benzoyl-TE14011) (Tamamura et al., 2003b).
4F-benzoyl-TN14003 and 4F-benzoyl-TE14011 show strong
anti-HIV activity in vitro, antimetastatic activity against
breast cancer and melanoma, and anti–rheumatoid arthri-
tis activity in experimental models (Tamamura et al., 2003c,
2004; Takenaga et al., 2004). Using the b-hairpin structure
of the natural product polyphemusin II and its analogs as
a template, another series of macrocyclic template-bound
b-hairpin mimetics was developed in iterative cycles, yielding
compounds such as POL3026, also known as CVX15 (DeMarco
et al., 2006) (Fig. 1). SAR studies on T140 identified four
indispensable amino acids (Arg2, Nal3, Tyr5, and Arg14)
responsible for its bioactivity (Fujii et al., 2003). These
residues were therefore used to design cyclic pentapeptides,
enabling the development of low-molecular-weight CXCR4
antagonists with bioactivities comparable to T140, including
FC131 (Fujii et al., 2003). Multiple series of FC131 were
developed aiming to reduce its peptide character and increase
drug-likeness (Tamamura et al., 2005a-b), to generate confor-
mationally constrained analogs (Tamamura et al., 2005a, b),
and to develop bivalent ligands to study CXCR4 dimers
(Tanaka et al., 2010). FC131 and derivatives are also agonists
of ACKR3 (Oishi et al., 2015).
Other peptidomimetics not using polyphemusin II as a basis
include peptides that mimic HIV proteins and mimetics of
CXCR4 domains and of its ligand CXCL12. ALX40-4C was
designed to mimic the basic domain of Tat, the HIV-1 trans-
activation protein. It is a nine-Arg polypeptide that includes
D-amino acids and terminal protection for stabilization, and it
has been proven to inhibit the use of CXCR4 byHIV-1 (Doranz
et al., 1997). Multiple peptides were designed on the basis of
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the extracellular domain of CXCR4 (N-terminus and extra-
cellular loops). Interactions between the highly conserved,
positively charged residues of glycoprotein 120 (gp120) from
the HIV envelope and the negatively charged extracellular
domain of CXCR4 are key for the binding of gp120 to CXCR4
and ulterior entrance of the virus into the cell. These peptides
show different ranges of anti-HIV activity (Hashimoto et al.,
2013; Chevigné et al., 2014). In one particular study peptides
were designed to mimic the N-terminus and extracellular
loops 1 and 2, both in a linear and cyclic structure. All pepti-
des show anti-HIV activity, but the cyclic peptides are
more potent and less cytotoxic (Hashimoto et al., 2013).
A CXCR4 ECL2-based peptide also inhibits ACKR3 inter-
nalization (Chevigné et al., 2014). A ligand-based approach
used the motif Aro-Aro-Arg, where Aro is an aromatic
residue, for peptidomimetics design. This motif is present
in CXCL12 and also found in vMIP-II in reverse orientation,
i.e., Arg-Aro-Aro. Four peptides, called R, S, T, and I, inhibit
CXCL12-dependent cell migration, and decrease cancer
growth and metastases in vitro. One particular CXCR4-
binding cyclopeptide, POL6326 (Balixafortide), has pro-
gressed into clinical studies. The results for phase I studies
have been published (Karpova et al., 2017; Pernas et al.,
2018), and a phase III clinical trial was launched in early
2019 to evaluate the antagonist in combination with eribu-
lin for the treatment of patients with metastatic breast
cancer. Balixafortide is the only CXCR4 antagonist in
development for breast cancer (ClinicalTrials.gov Identifier:
NCT03786094).
Some studies report the use of chimeras consisting of
different CXCR4 modulators. Examples include a chimera
consisting of CXCL12 and the peptide T140 that acts
as a partial CXCR4 agonist (Lefrançois et al., 2011), and
one consisting of CXCL12 and the small-molecule antagonist
IT1t, reported to be an antagonist with low affinity (Mona
et al., 2016).
A chemokine-like chimera, named CXCL11_12, has been
reported as a high-affinity ACKR3-selective ligand. The struc-
ture of the engineered chimera consists of the N-terminus of
CXCL12 and the main body and C-terminus of CXCL11, and
the study showed the internalization of CXCL11_12 by mouse
ACKR3, making the chimera a useful tool to study ACKR3
(Puddinu et al., 2017; Ameti et al., 2018).
Pepducins
A specific subset of lipid-modified peptide-basedmodulators
called pepducins (Covic et al., 2002; (O’Callaghan et al.,
2012a,b) has been described for CXCR4 (Table 1). The peptide
sequence of a pepducin is derived from one of the intracellular
loops of a target GPCR and is typically connected to palmitic
acid or other fatty acids via an amide bond. Pepducins can act
as positive or negative allosteric GPCR modulators, and
experimental evidence (Covic et al., 2002; Wielders et al.,
2007; Janz et al., 2011) and modeling (Planesas et al., 2015)
suggest that they bind to an allosteric, intracellular site on the
target receptor. Their lipid tail is crucial for activity as it
probably anchors the pepducin in the cell membrane (Covic
et al., 2002).
ATI-2341 (Tchernychev et al., 2010) (Fig. 3), which is
derived from the first intracellular loop of CXCR4, is probably
the best described pepducin for CXCR4 and acts as a biased
agonist (Quoyer et al., 2013), activating multiple G protein-
activated signaling pathways downstream of CXCR4. ATI-
2341 has been shown to variously cause a Gi-mediated
inhibition of cAMP production, stimulate calciummobilization,
modify polymorphonuclear neutrophil mobilization, and elicit
chemotaxis (Tchernychev et al., 2010). CXCR4 internalization
TABLE 1
Pepducins described for CXCR4a
All C-terminal ends are modified to an amide; N-terminal end Pal is Palmitic acid; all listed pepducins for CXCR4 are derived from ICL1 except PZ-210. R1 5 R2 5 L-Photo-
Leucine.
CXCR4 Sequence
ICL1 63-MGYQKKLRSMTDKYRLHL-80
ICL3 224-SKLSHSKGHQKRKALK-239
Pepducin Sequence Function Ref.
ATI-2341 Pal
–MGYQKKLRSMTDKYRL
Biased agonist Tchernychev et al., 2010, Janz et al.,
2011, Quoyer et al., 2013
ATI-2346 Pal -KKLRSMTDKYRLH PAM Quoyer et al., 2013, Tchernychev et al.,
2010
ATI-2756 Pal
-GGYQKKLRpHTDKYRL
SAR analog of ATI-2341 with
improved plasma stability
Quoyer et al., 2013, Carlson et al., 2012
ATI-2766 R1-GGYQKK-R2-SATDKYRL Fluorescent pepducin Janz et al., 2011
PZ-218 (x4pal-i1) Pal -MGYQKKLRSMTD Antagonist Kaneider et al., 2005, O’Callaghan et al.,
2012a,b
Intracellular loops (ICL PZ-
210 (x4pal-i3)
Pal
-SKLSHSKGHQKRKALK
Antagonist Kaneider et al., 2005, O’Callaghan et al.,
2012a-b
ICL, intracellular loops.
aTchernychev et al. (2010) and its supporting information mentions further screening of more intracellular loop 1 pepducins in a chemotaxis assay. All show lower potencies
than ATI-2341, and sequences were partly not mentioned; the patent US 9,096,646 (McMurry et al., 2015) of CXCR4 pepducins mentions further pepducins from all three
intracellular loops that were partially screened.
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has also been observed following addition of ATI-2341 in
imaging techniques (Tchernychev et al., 2010; Dimond et al.,
2011). However, it has also been shown using flow cytometry or
bioluminescence resonance energy transfer (BRET)-based
approaches that ATI-2341 does not or only partially recruits
b-arrestins to cell surface CXCR4 and this appears to be
accompanied by a weak receptor internalization compared
with CXCL12. The authors suggest that these results might
be attributable to different CXCR4 phosphorylation profiles
promoted by ATI-2341 versus CXCL12 (Quoyer et al., 2013).
The ability of ATI-2341 to recruit G proteins (Ga,i, G13) has
also been investigated with BRET using a C-terminal renilla-
luciferin 2-monooxygenase-tagged CXCR4 and a yellow fluo-
rescent protein-tagged G protein. These studies concluded
ATI2341 activates Ga,i in preference to G13, and this recruit-
ment of G proteins is sensitive to pertussis toxin (Quoyer et al.,
2013). Consistent with its low efficacy for b-arrestin recruit-
ment, ATI-2341 also recruits lower levels of G protein-coupled
receptor kinases (GRK) 2 and 3 (Quoyer et al., 2013). Further-
more, ATI-2341 only promotes protein kinase C–mediated
phosphorylation of serine residues at theC-terminus of CXCR4,
but not by GRK6 (Quoyer et al., 2013).
Publications concerning ATI-2341 also describe pepducins
with lower potencies and a fluorescent pepducin, ATI-2766,
which can crosslink to CXCR4 and N-terminal-truncated
variants (Janz et al., 2011). Mice and nonhuman primates
release hematopoietic stem/progenitor cells from bone mar-
row after intravenous administration of ATI-2341, suggesting
the potential of pepducins to induce stem cell mobilization
(Tchernychev et al., 2010; O’Callaghan et al., 2012a).
PZ-218, another CXCR4 first internal loop pepducin, and PZ-
210, derived from the third intracellular loop, are also CXCR4
antagonists (Kaneider et al., 2005; O’Callaghan et al., 2012b).
They both antagonize CXCL12-mediated calcium mobilization
in human neutrophils (Kaneider et al., 2005; O’Callaghan et al.,
2012b), inhibit extracellular signal–regulated kinase activation
in Jurkat cells (O’Callaghan et al., 2012b) and inhibit CXCL12-
mediated chemotaxis in a range of cell lines (Kaneider et al.,
2005; O’Callaghan et al., 2012). Combined with rituximab,
these antagonist pepducins increase the cytotoxicity in leuke-
mia cells from patients with chronic lymphocytic leukemia
(Kaneider et al., 2005; O’Callaghan et al., 2012b) and in
a mouse model of disseminated lymphoma—the combination
with rituximab leads to an increase in survival (O’Callaghan
et al., 2012b).
Small-Molecule Modulators of CXCR4 and
ACKR3
The field of small-molecule CXCR4 antagonists has been
reviewed before in detail (Zhan et al., 2007; Peng et al., 2018).
Therefore, we focus on key examples. In a manner similar to
the peptidomimetics that were first identified, the first small-
molecule modulators of CXCR4 were initially identified as
inhibitors of HIV entry. The most prominent CXCR4 antago-
nist, AMD3100, was discovered in 1994 as a highly potent and
selective inhibitor of HIV entry (De Clercq et al., 1994). The
actual target of AMD3100 turned out to be the CXC-chemokine
receptor CXCR4, which is used by T-lymphotropic HIV strains
to enter immune cells (Donzella et al., 1998). A phase I clinical
trial with AMD3100 as an anti-HIV drug showed an increase in
the white blood cell counts as an unexpected side effect.
Further studies showed that AMD3100 specifically increases
cluster of differentiation 34 (CD341) hematopoietic stem cell
(HSC) counts by antagonism of the CXCL12 interaction with
CXCR4. De Clercq (2009) wrote a comprehensive overview of
the discovery path of AMD3100 and recently reviewed the
potential application of AMD3100 in other diseases, like the
warts, hypogammaglobulinemia, infections, and myeloka-
thexis (WHIM) syndrome (De Clercq, 2019).
As of 2008, AMD3100 (Fig. 4) [international nonproprietary
name: plerixafor] is the first CXCR4 modulator approved
for clinical use (Mozobil by Genzyme) in coadministrationwith
granulocyte colony-stimulating factor for the mobilization
of CD341 cells in non-Hodgkin lymphoma (NHL) and multi-
ple myeloma (MM). AMD3100 is still being examined in
clinical trials for expanded use (ClinicalTrials.gov Identi-
fiers: NCT03277209, NCT02231879, NCT01318317), but all
phase II and phase III clinical trials for AMD3100 involve
mobilization of HSCs in NHL, MM, and other hematologic
diseases. Trials with AMD3100 for the treatment of HIV show
a limited safety profile with heart- and gastrointestinally
related adverse effects with the dose/time that would give
a small therapeutic effect. Moreover, since AMD3100 is also
not orally bioavailable, further development for the treatment
of HIV-1 infection was discontinued (Hendrix et al., 2000,
2004). A series of ongoing trials are focused on the use of
AMD3100 in combination with chemotherapy. The effect of
metal chelation by AMD3100 has been assessed. For example,
a complex with Zn21 ions shows slightly higher anti-HIV
activity, whereas complexes of Cu21 andPd21 result in a 4-fold
and a 7500-fold less activemolecule comparedwith AMD3100,
respectively (Bridger et al., 1995).
An initial attempt to improve the bioavailability of
bicyclams such as AMD3100 resulted in the discovery of
AMD3465 with a more drug-like structure, and an improved
potency. However the oral bioavailability was not improved
(Hatse et al., 2005).
One of the first nonmacrocyclic small modulators that has
been discovered is WZ811 (Zhan et al., 2007). However, this
1,4-phenylenedimethanamine has a poor pharmacokinetic
profile owing to rapid metabolism. Optimization of WZ811
led to the discovery of MSX-122, a partial CXCR4 antagonist
Fig. 3. Schematic representation of ATI-2341 (peptide on the left) and
CXCR4 (green) showing the amino acids of intracellular loop 1; represent-
ing the proposed localization of the pepducin in relation to the GPCR with
the lipid of the pepducin serving as an anchor in the cell membrane and an
intracellular interaction site.
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with superior Matrigel invasion inhibition compared with
AMD3100. Additionally, MSX-122 is a selective inhibitor of
the Ga,i pathway (cAMP inhibition), leaving the alternative
Ga,q (calcium flux) pathway untouched. As a result, MSX-122
has a distinct functional profile of inhibition of CXCR4-
mediated inflammation, metastasis, and chemotaxis without
mobilizing stem cells (Liang et al., 2012). Interestingly, the
ligand cannot block 125I-CXCL12 binding, whereas CXCL12
can block fluorine-18-labeled MSX-122 from binding to
CXCR4, supporting the hypothesis that the small-molecule
ligand blocks certain receptor functions via interference with
CXCR4/CXCL12-mediated signaling (IC50 5 10 nM). More-
over, the therapeutic potential of MSX-122 was evaluated in
three different murine models (Liang et al., 2012) and it was
the first analog of AMD3100 to enter a clinical trial phase I
in 2007 inpatientswith refractorymetastatic or locally advanced
solid tumors (ClinicalTrials.gov identifier: NCT00591682).
However, the trial was suspended in 2008 and no further
details on the clinical effectiveness of MSX-122 have been
published.
In an attempt to address metabolic instability, another
series of inhibitors were synthesized bearing scaffolds with
a reduced electron density by introduction of pyrimidines,
halogens, and other substituents. This led to the discovery of
508MCl, which displays subnanomolar potency in a CXCL12-
mediated inhibition of cAMP production (IC50 5 0.8 nM); it is
almost 1000-foldmore potent thanAMD3100 (IC505 695 nM).
508MCl has also been evaluated in vivo for inflammation, lung
fibrosis, and tumor metastasis, and it was effective in all
tested model systems. Although its biologic activity in vitro
Fig. 4. Selected small-molecule CXCR4 antagonists. aInhibition of CXCL12-mediatedMatrigel invasion; bCXCR4 125I-CXCL12 inhibition binding assay.
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and in vivo is favorable, it has a very short half-life of about
15 minutes and is not orally bioavailable (Zhu et al., 2010).
Another CXCR4 inhibitor developed by TaiGen Biotechnol-
ogy, compound TG-0054 (also known as burixafor) (Fig. 4)
was applied in injections of poly(L-lactide) microparticle
formulation for the treatment of choroid neovascularization
(Shelke et al., 2011). In addition, its potential for treating the
aftermath of a myocardial infarction was demonstrated in
a pig model (Hsu et al., 2015), and the molecule has entered
a clinical phase I trial to assess its use as a sensitizer in
metastatic prostate cancer chemotherapy that would mobilize
the cancer cells into the blood (NCT02478125) and a phase II
trial for the mobilization of HSCs in patients with non-
Hodgkin lymphoma or multiple myeloma (NCT01458288).
A high-throughput screening campaign to search for new
CXCR4 antagonists revealed quinoline and quinazoline deriv-
atives as candidates, where the hit ligand shows a 5-fold
higher affinity in inhibition of 125I-CXCL12 binding to CXCR4
(IC50 5 4.7 nM) compared with AMD3100 (IC50 5 213 nM)
(Wu et al., 2012). Another potent quinazoline-based selective
CXCR4 antagonist (compound 1, Fig. 4) was characterized
(IC50 5 13 nM) as a potential tool to study diseases mediated
by the CXCR4/CXCL12 axis, was tested in vivo, and showed
a therapeutic potential in an acute kidney injury disease
model (Wu et al., 2015a).
Recently, virtual fragment screening, synthesis, and de-
sign have led to a series of N-substituted piperidin-4-yl-
methanamine derivatives (for example, compound 2 in
Fig. 4). Adlere et al. (2019) showed that small structural
ligand changes lead to distinct interactions with CXCR4 and
CXCL12, supporting the study with three-dimensional quan-
titative SAR (3D-QSAR) and proposed binding models.
Other purine-based small molecules display subnanomo-
lar EC50 values for CXCR4-mediated HIV inhibition (up
to 0.51 nM), show a better functional profile in chemo-
taxis than AMD3100, and mobilize CXCR41 cells in mice
(Wu et al., 2015b).
The 1,4-phenylenedimethanamine core, as in AMD3100
and AMD3465 (Fig. 4), is a prominent feature among
CXCR4 small-molecule antagonists and serves as a starting
point for ligand-based discovery of new analogs for im-
proved potency against CXCR4. Likewise, several amide-
sulfonamide derivatives have CXCR4 binding properties
and outperform AMD3100 in Matrigel invasion inhibition
(Bai et al., 2017a, 2017b).
Despite the potency of AMD3100 and other cyclam deriva-
tives at CXCR4, oral bioavailability remains an issue for these
lipophilic compounds. A stepwise discovery of nonmacrocy-
clam derivatives through structural modifications eventu-
ally led to the discovery of the first orally available, potent,
and selective small molecule targeting CXCR4—AMD11070
(which was initially developed for the treatment of HIV-1
infection; Bridger et al., 2010; Skerlj et al., 2010). AMD11070
has successfully completed phase I and phase II clinical trials
for the treatment of HIV (NCT00089466) and is also in a phase
II/III trial (Dec 2016, NCT03005327) as a potential treatment
of WHIM syndrome. Phase I trials of a combination therapy
with pembrolizumab for the treatment of melanoma started
in June 2016 (NCT02823405).
With AMD11070 as a basis, a variety of structural mod-
ifications have been made to improve metabolic stability,
anti-HIV activity, and pharmacokinetic (PK) properties
(Gudmundsson et al., 2009a,b; Catalano et al., 2010), includ-
ing a highly potent hybrid-piperazine derivative, GSK812397
(Fig. 4), a nontoxic, selective, noncompetitive antagonist of
CXCR4 with low nanomolar antiviral activity against a broad
range of X4-utilizing strains of HIV-1 and with good pharma-
cokinetics (Jenkinson et al., 2010).
Among other AMD11070 derivatives targeting CXCR4
(Miller et al., 2010; Skerlj et al., 2011; Zhao et al., 2015),
tetrahydroisoquinoline-based TIQ-15 (Fig. 4) was identified as
a highly active scaffold for CXCR4 inhibition (Truax et al.,
2013). More recently, new TIQ-15-derived CXCR4 antagonists
were reported. Structural alterations of the molecule have
led to improved properties, including enhanced metabolic
stability and a reduced off-target liability, such as toward
cytochrome P450 2D6 (Jecs et al., 2017; Wilson et al., 2017),
and improvement of intestinal absorption (Miller et al., 2018).
Overall, evidence suggests that TIQ-15 might have potential
therapeutic application in anticancer therapy.
A high-throughput screening campaign at Novartis led to
the discovery of a series of orally bioavailable isothiourea-
derived CXCR4 antagonists (Thoma et al., 2008). Optimiza-
tion of one of the hits, isothiourea IT1a (NIBR-1816), yielded
the highly potent and selective ligand IT1t (Fig. 4), and its
therapeutic potential as anti-AIDS drug was evaluated. The
X-ray crystal structure of IT1t cocrystallized with CXCR4 is
available (Wu et al., 2010) and is advancing structure-based
ligand discovery studies for small molecules targeting
CXCR4 (Mysinger et al., 2012; Cox et al., 2015; Das et al.,
2015). Noteworthy among the small molecules, including the
ones found via virtual screening approaches, some potent
ligands, although retaining a functional effect, did not displace
125I-CXCL12, indicating the allosteric interactions ormultiple
binding sites for small molecules.
Another approach to preventing CXCR4 signaling with
small molecules is the targeting of CXCL12; thus, small
molecules would act as chemokine scavengers. A set of small
molecules with a micromolar range of affinities was discov-
ered through a virtual screen for compounds that bind to
CXCL12 occupied by CXCR4 residues D20 and sY21 and
using the nuclear magnetic resonance structure of the
receptor-peptide complex (Veldkamp et al., 2010; Ziarek
et al., 2012). Another series of ligands that inhibit CXCL12-
CXCR4 interaction via binding of the chemokine, called
“chemokine neutraligands,” was identified after screening
of a small (3200 molecules) chemical library in a fluorescent
binding assay on living cells, where a single submicromolar
CXCL12 binder that inhibits CXCL12-evoked CXCR4 in-
ternalization (Fig. 4, compound 3, IC50 5 150 nM) was
identified (Hachet-Haas et al., 2008). Additionally, chalcone
3 was also found to be an inhibitor of CXCL12-mediated
ACKR3 activation, further establishing its mechanism of
action via the scavenging of the chemokine. A prodrug analog
of a neutraligand 2 locally inhibits airway inflammation in
a mouse model (IC50 5 10 nmol/kg) (Gasparik et al., 2011).
Recently, modifications of the CXCL12 neutraligand 2 led
to a discovery of a novel non-Michael acceptor with anti-
inflammatory effect, LIT-927 (Fig. 4), with better solubility
(Regenass et al., 2018).
To summarize the current status in the field of small-
molecule modulators for CXCR4, it is fair to state that
AMD3100, AMD11070, and IT1t still remain as reference
ligands in many studies targeting CXCR4/CXCL12-mediated
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processes. Yet, there are several small molecules showing
similar or better properties regarding potency, affinity, PK, and
ADME properties. Owing to the early stage of the develop-
ment or incomplete characterization, they are arguably not yet
considered as reference molecules.
In contrast to reports on CXCR4, there are only a small
number of studies describing small molecules that target
ACKR3. In 2009, the classic CXCR4 antagonist AMD3100
was shown to be an allosteric ACKR3 agonist at high
concentration (.10 mM), enhancing CXCL12 binding to
ACKR3, and, alone, recruiting b-arrestin to ACKR3 in aBRET
assay with a small (13%) increase in BRET (Kalatskaya
et al., 2009). Interestingly, preincubation with isothiourea
IT1a (NIBR-1816) significantly affects the uptake of chime-
ric ACKR3-selective ligand CXCL11_12, indicating that
IT1a targets both receptors, although possibly by different
mechanisms (Puddinu et al., 2017).
Among a series of substituted styrene amides patented by
Chemocentryx, VUF11207 (Fig. 5) was found to be a high-
affinity ACKR3 agonist able to recruit b-arrestin2 and
reduce ACKR3 surface expression (Wijtmans et al., 2012).
Indeed, Chemocentryx has developed a number of ACKR3
ligands. A selective ACKR3 agonist CCX771 (IC50 4.1 nM)
(Zabel et al., 2009, 2011; Yamada et al., 2015) is patented by
the company (structure not revealed) and is often used in
the characterization of ACKR3. CCX771 inhibits tumor
growth, lung metastasis, and tumor angiogenesis in vivo,
and further evidence suggests that the CXCL12-ACKR3
autocrine loop affects proangiogenic properties of tumor
endothelial cells (Yamada et al., 2015). However, the
signaling pathway and the mode of action of this small
molecule are still not clear. VUF11207 and CCX771 block
X7-HIV-1-strain entry with IC50 approx. 50 nM. VUF11207
is selective toward the HIV-1 HE #10 viral strain and both
compounds do not block the HIV-2 EHO strain. CCX771 was
further evaluated in HIV-1 replication using quantitative
real-time polymerase chain reaction showing HIV entry-
blocking properties (D’Huys et al., 2018).
Another Chemocentryx ligand, CCX777 (Fig. 5), can be used
as a tool probe for mapping the binding pocket of ACKR3.
The compound acts as a partial agonist of ACKR3 with an
efficacy of 52% relative to the endogenous ligand and potency
of 33 nM (8.5 nM for CXCL12) in b-arrestin2-recruitment
assay (Gustavsson et al., 2017). Using radiolytic footprint-
ing, two different complexes of ACKR3 with CCX777 and
CXCL12 were compared (Gustavsson et al., 2017). Another
ACKR3 ligand, compound 4 (Fig. 5), inhibits CXCL12-
induced tube formation in human umbilical vein endothe-
lial cells (0.96 nM), demonstrating selective ACKR3 agonist
potential as angiogenesis inhibitors. Moreover, it recruits
b-arrestin2 in a BRET assay. An antagonistic antibody
for ACKR3 did not affect tube formation under the same
conditions (Uto-Konomi et al., 2013).
A novel 1,4-diazepine-ACKR3 ligand was discovered using
the chemical scaffold of one of the Chemocentryx ligands as
a basis. Exhaustive SAR studies led to a hit, compound 5
(Fig. 5), with equal high-affinity agonism on human (13 nM)
and mouse (51 nM) ACKR3. In vivo tests showed reduction of
cardiac fibrosis in a mouse model (Menhaji-Klotz et al., 2018).
A range of pharmacological data in this study can facilitate the
use of this ligand to study ACKR3.
Very recently, Nalawansha et al. (2019) showed a proof-of-
concept study of heterodimeric molecules, termed “ENDosome
TArgeting Chimeras” (ENDTACs), and their internalization
and degradation of an intracellular recombinant enhanced
green fluorescent protein (eGFP) and Halotag7 (HT7) fusion
by capturing ACKR3. ENDTACs-1–4 (Fig. 5) were obtained
using a warhead of VUF11207, a potent ACKR3 agonist (vide
supra), that incorporated an HT7-recruiting chloroalkane at
a position of one of the methoxy groups of VUF11207.
ENDTACs-1–4 display only slightly reduced potency
(EC50 111–158 nm) compared with the parent VUF11207
Fig. 5. Structuresof selectedsmall-molecule
ACKR3 agonists. aACKR3 125I-CXCL12 in-
hibition binding assay. bb-arrestin re-
cruitment BRET assay. cInhibition of
CXCL12-induced tube formation in hu-
man umbilical vein endothelial cells, the
exact EC50 for b-arrestin recruitment
BRET assay not given. dPulse chase Tango
assay (compound alone). ePulse chase
Tango assay for precomplexed compound.
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(EC50 68 nM, same assay.) Additionally, prereacted
ENDTACs1–4:eGFP-F complex showed similar potency for
ACKR3 activation (EC50 169–287 nm) (Nalawansha et al., 2019).
CXCR4 and ACKR3 Radioligands
For the characterization of ligand binding to GPCRs in
systems in vitro and in vivo, tagged molecules are often
required tomeasure or visualize ligand-GPCR binding. Radio-
ligands are very useful tools for such a purpose.
For in vitro studies, a commonmethod is to use radiolabeled
peptides whose tyrosine residues are labeled with iodine-125
(125I). This technique has been used for labeling CXCL12
since the initial discovery of CXCR4 as a chemokine recep-
tor for CXCL12 (Bleul et al., 1996; Oberlin et al., 1996;
Hesselgesser et al., 1997, 1998; Di Salvo et al., 2000). The use
of 125I-CXCL12 remains a robust method for the measure-
ment of the binding of ligands to CXCR4, but as CXCL12 also
binds to ACKR3 some interference can be caused if both
receptors are present in the same cell population. As ACKR3
has a 10-fold higher affinity for CXCL12, 125I-CXCL12 is also
used for ACKR3 binding studies. It is worth noting that the
endogenous peptide CXCL12 may not compete with the
small molecules binding to the same receptor. A small-
molecule CXCR4 allosteric modulator, MSX-122, has been
18F-radiolabeled and used for characterization of its non-
labeled analog in vitro (Liang et al., 2012). Radioiodination
has been applied to a number of selective endogenous CXCR4
ligands, such as the highly specific anti-CXCR4 monoclonal
antibody (mAb) 12G5 (Endres et al., 1996), which is less
affected by mutations of CXCR4 than CXCL12 (Thiele et al.,
2014). Others include the BKT-140 (4-F-benzoyl-TN14003)
(Fig. 6) analog Ac-TZ14011 for in vivo and in vitro studies
(Han et al., 2010) and the 125I-labeled pentapeptide FC131
(Koglin et al., 2006; Demmer et al., 2011a).
For in vivo imaging of receptor expression, the use of
radiotracers is practically indispensable. Depending on
the radioisotope that is used, the basis of in vivo imaging
is gamma ray detection (single-photon emission computed
tomography or SPECT) or detection of photon pairs resulting
from positron annihilation (positron-emission tomography
or PET). Nowadays, PET is a detection method used both
in clinics and research and PET tracers are useful tools in
theranostics (Yordanova et al., 2017).
89Zr-labeled ACKR3-mAb (clone 11G8) was evaluated
in vitro and in vivo by PET, which showed enhanced
labeled-antibody uptake in high-ACKR3-expressing tumors,
and serves as a viable diagnostic marker (Behnam Azad
et al., 2016).
Radiofluorinated ligands are commonly used for PET tracer
development. For CXCR4-expressing tumor imaging, the
peptide BKT-140 isotopologue 4-[18F]Bn-TN14003 (Jacobson
et al., 2010) and [18F]fluoropropionate-labeled Ac-TC14012
peptide (Zhang et al., 2013) show a high tumor uptake and
low nonspecific binding. 18F has also been incorporated in
the FC131 analog CCIC15, in which the arginine residue
was changed to a (2-fluoroethyl)-1H-1,2,3-triazol-4-ylalanine
(George et al., 2013); however, no specific tumor uptake was
detected. An 18F-labeled noncyclamAMD3465 analogwas also
evaluated as a CXCR4PET tracer, which revealed that reduced
receptor binding and fast excretion are the limiting factors
for CXCR4 imaging (Demoin et al., 2016). An 11C-labeled
derivative of AMD3465 (Fig. 6), however, was used for the
determination of the receptor occupancy by AMD3100 in a C6
glioma tumor model (Hartimath et al., 2014, 2017).
Chelation of radioactive metal ions is another well known
technique for labeling PET tracers. Small-molecule tracers
such as 64Cu-AMD3100 (Fig. 6) (Jacobson et al., 2009; De Silva
et al., 2011; Weiss et al., 2012), 64Cu-labeled AMD3465 and its
bridged analog (De Silva et al., 2011; Woodard et al., 2014)
Fig. 6. Selected CXCR4-specific PET tracers.
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and, recently, 99mTc-AMD3465 (Zhang et al., 2018) have been
used as tools for successful identification of CXCR41 tumors.
BKT-140 has also been used as a template for metal-ion
chelates. This was enabled by conjugation of either the D-
lysine or both lysine residues of the peptide with 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator
moieties (68Ga-DOTA-4-FBn-TN14003, Fig. 6) (Hennrich et al.,
2012; Jacobson et al., 2012). Moreover, specificity of BKT-140
was improved and this peptide has been labeled with 68Ga31s,
resulting in 68Ga-NOTA-NFB using 1,4,7-triazacyclononane-
N,N9,N99-triacetic acid as a chelator (Fig. 6), which was
successfully applied in glioma patients (Wang et al., 2015).
The N-methylated derivative of the CXCR4-selective peptide
FC131 was also developed as a PET tracer. Substitution of the
N-methylated D-arginine for a N-methylated D-ornithine and
subsequent conjugation with a benzoic acid-linked DOTA
chelating with 68Ga31 resulted in 68Ga-pentixafor (Fig. 6)
(Demmer et al., 2011b). The tracerwas used to localizemultiple
myeloma and other tumor types, visualization of CXCR4-
expression after acute myocardial infarction, in atherosclerotic
plaques, and for the identification of leukocytes after trans-
plantation (Herrmann et al., 2015; Thackeray et al., 2015;
Derlin et al., 2016, 2017; Lapa et al., 2016a,b; Rischpler et al.,
2016; Vag et al., 2016; Hyafil et al., 2017; Watts et al., 2017).
A tyrosine monoiodinated analog of FC131, pentixather, la-
beledwith 177Luprovides a tracerwith higher liver uptake than
68Ga-pentixafor but also high tumor uptake, making it prom-
ising for clinical application in combinationwith 68Ga-pentixafor
(Schottelius et al., 2017). Ulocuplumab, a CXCR4-selective
humanmonoclonal antibody labeledwith 89Zr, shows a specific
accumulation in CXCR4 expressing tumors (Azad et al., 2016).
Fluorescent Probes
Fluorescent labeling of appropriate chemokine receptor
ligands provides a unique way to study the complex biologic
interactions of CXCR4 and ACKR3. Early efforts to develop
a CXCR4-targeting fluorescent probe used an AMD3100
derivative incorporating a rhodamine fluorophore for visu-
alization (Khan et al., 2007) (Fig. 7). Metalation of AMD3100
using Zn21, Ni21, and Cu21 ions yields highly stable metal
complexes and even increases affinity towardCXCR4 (Gerlach
et al., 2003). Binding data of the fluorescent probe disclosed by
Khan et al. (2007) were not reported. However, flow cytometry
studies showed that the copper-complexed probe actively
competes with CXCR4-specific antibodies. The uncomplexed
fluorophore displays no CXCR4-specific binding, indicat-
ing that metal ions are necessary for receptor binding by
conformationally restricting the cyclam.
Another fluorescent derivative of AMD3100 has also been
reported by (Knight et al. (2011) and used an anthracene
moiety to link two cyclam rings (Fig. 7). The fluorescent ligand
(L1) inhibits binding of anti-CXCR4 antibody 12G5, albeit with
a significantly reduced affinity for CXCR4 compared with
AMD3100 (IC50 5 0.25–0.9 mM for L
1, IC50 5 10 nM for
AMD3100). Further exploration of the AMD3100 scaffold led
to the discovery of a boron-dipyrromethene-labeled (BODIPY)
CXCR4 antagonist (Fig. 7) (Poty et al., 2015). The use of
Fig. 7. Selected fluorescent probes targeting CXCR4.
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a BODIPY as a fluorophore is well documented and has
several advantages (Wiederschain, 2011). The BODIPY-
conjugated probe displays binding properties inferior to the
parent ligand.Whereas AMD3100 has an EC50 of 11 nM in an
anti-HIV assay, the most potent AMD3100-BODIPY conju-
gate gives an EC50 of only 0.8 mM. Furthermore, this
fluorescent conjugate was not found to compete directly with
CXCL12 in a calcium flux competition assay. Overall these
imaging probes with a small-molecule basis display poor
pharmacological properties for CXCR4, showing attenuation
in affinity compared with parent AMD3100, thus limiting
their applicability.
A cyclic peptide-based fluorescent probe Ac-TZ14011 dis-
plays an IC50 of 1.2 nM and 2.6 nM in an CXCL12 binding
assay and a Ca21 mobilization assay, respectively (Hanaoka
et al., 2006). Utilizing the D-lysine of this peptide, it was
possible to introduce carboxytetramethylrhodamine-based
and fluorescein dyes (Nomura et al., 2008) with the resulting
fluorescent probes displaying IC50 values of 14 and 11 nM,
respectively, in a competitive binding assay. Use of Ac-
TZ14011 in the development of CXCR4-targeting probes was
further exploited by labeling the peptide with a multifunc-
tional single attachment point reagent containing a DTPA
(diethylenetriaminepentaacetic acid) chelate anda fluorescent
dye (Fig. 7) (Kuil et al., 2011). Although a decrease in binding
affinity was observed (KD5 177.16 37.2 nM for the conjugate,
KD 5 8.61 6 1.42 nM for the unlabeled peptide), the probe
was successfully used to image CXCR4-expressing cells both
in vitro and in vivo. A different fluorescent peptide was also
developed consisting of a fluorescein isothiocyanate conju-
gated to DV1 (Yang et al., 2014). DV1 is an all D-amino acid
analog of V1, a synthetic peptide derived from the N-terminus
of the viral macrophage protein vMIP-II (Zhou et al., 2002).
This fluorescent conjugate shows a binding affinity for CXCR4
in the micromolar range and was competitively displaced by
small molecules AMD3100 and IT1t, as well as by parent
peptide DV1.
Small-molecule- or peptide-based fluorescent probes that
specifically target ACKR3 have not been reported to date.
Fluorescence-based (imaging) techniques so far have instead
relied on the use of fluorescently tagged CXCL12- or ACKR3-
specific antibodies (Meincke et al., 2011; Humpert et al., 2012;
Masuda et al., 2012; Melo et al., 2018).
Concluding Remarks
In this review, we describe the relationships between ligand
binding and structural motifs of the two related chemokine
receptors CXCR4 and ACKR3 and provide an overview of the
knownmodulators of both GPCRs, with a specific emphasis on
validated research tools.
Structurally, CXCR4 shows the same common features
as other GPCRs of the chemokine receptor subclass. The
N-terminal end of the receptor is of particular interest for
binding of the endogenous ligand CXCL12, which binds in the
orthosteric binding site, which can be divided into aminor and
major pocket (Arimont et al., 2017). This orthosteric binding
site overlaps with the binding site of several small molecules
and peptide ligands as seen in crystal structures and deduced
frommutational studies (Wu et al., 2010; Arimont et al., 2017).
CXCR4 and ACKR3 both bind CXCL12 (Hesselgesser et al.,
1998; Balabanian et al., 2005), the viral chemokine vMIP-II
(Kledal et al., 1997; Szpakowska et al., 2016), and b-defensins
2 and 3 (Quiñones-Mateu et al., 2003; Feng et al., 2006), but
they also have endogenous ligands binding only one of the
two. CXCR4 binds ubiquitin (Saini et al., 2010) and ACKR3
binds to CXCL11 (Burns et al., 2006) and adrenomedullin
(Klein et al., 2014).
Most CXCR4 peptide ligands are derived from polyphemu-
sin II and have been shown to inhibit the ability of HIV-1 to
infect cells (Murakami et al., 1997). There has been an array
of peptide variants with this original structure as a basis
showing different affinities, potencies, stabilities, and selec-
tivities and some of them also interact with ACKR3 (Oishi
et al., 2011). Other peptidomimetics have as a basis peptides
that mimic HIV proteins, CXCR4 domains, or parts of
CXCL12 and show that they also inhibit the ability of HIV-1
to infect cells (Hashimoto et al., 2013; Chevigné et al., 2014).
The last group of peptide ligands consists of chimeric ligands
fusing two ligands (Lefrançois et al., 2011, Mona et al., 2016).
Pepducins have been described as agonists and antagonists
for CXCR4, but not for ACKR3, (Tchernychev et al., 2010) and
although they are a new interesting class of receptor modu-
lators, their exact mode of action is unclear and designing new
pepducins is difficult. However, they act as an interesting
class of ligands with their postulated binding site being an
allosteric intracellular one (Covic et al., 2002; Wielders et al.,
2007; Janz et al., 2011).
AMD3100, AMD11070, and IT1t are currently the most
widely used CXCR4 small-molecule reference ligands, even
though there is a range of compounds showing similar or
better potency, affinity, and PK and ADME properties. The
first small molecules targeting CXCR4 were originally
identified as HIV-entry inhibitors, with the most prominent
compound approved for clinical use being AMD3100. This
drug is now used for the mobilization of CD341 cells in NHL
and MM rather than for HIV treatment (De Clercq et al.,
1994; De Clercq, 2009).
Apart from AMD3100-like compounds, nonmacrocyclic
modulators were discovered in various screens in efforts to
solve the problem of bioavailability. TG-0054 (burixafor) is in
clinical trials for assessing its use as a sensitizer in metastatic
prostate cancer (Shelke et al., 2011) and AMD11070 for the
treatment of HIV and WHIM syndrome (Bridger et al., 2010;
Skerlj et al., 2010).
Only a small number of compounds have been described as
modulators of ACKR3. Some of the CXCR4 ligands, such as
AMD3100 (Kalatskaya et al., 2009) and isothiourea IT1a
(NIBR-1816) (Puddinu et al., 2017), interact with ACKR3 at
high concentrations. VUF11207 (Wijtmans et al., 2012) and
CCX771 (Zabel et al., 2009, structure unpublished) have been
described as ACKR3 agonists, and CCX777 (Gustavsson et al.,
2017) acts as a partial agonist.
Radiolabeled and fluorescent ligands have been developed
as useful research tools. CXCL12 has been labeled using an
iodine-125 label on tyrosine residues and also with Alexa
Fluor 647 (Bleul et al., 1996; Oberlin et al., 1996; Hesselgesser
et al., 1997, 1998; Di Salvo et al., 2000). Radioiodination
has also been introduced to CXCR4 and ACKR3 antibodies
and peptides (Endres et al., 1996; Koglin et al., 2006; Han et al.,
2010; Demmer et al., 2011a; Behnam Azad et al., 2016).
Furthermore, small molecules have been labeled using an
array of radiolabels with different tracers (18F, 11C, 64Cu,
68Ga, 89Zr, or 177Lu) either as substitutes of unlabeled atoms
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or in a chelate complex. These small molecules can also be
labeled using fluorescent tags (Khan et al., 2007;Wiederschain,
2011). However, the tag often influences the binding properties
of the compounds owing to their size and they have to be studied
as a new compound. For ACKR3, only fluorescently labeled
antibodies and CXCL12 have been described as tools to label
the receptor.
Efforts to find suitable ligands for CXCR4 and ACKR3 are
a continuous process to provide the research community with
better research tools and to seize the therapeutic opportuni-
ties in the area of HIV infection and cancer. Continuing
structural biology efforts are of fundamental importance
for the understanding of drug-receptor interactions at both
GPCR proteins and for the ongoing drug discovery programs
targeting CXCR4 and ACKR3.
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